Spark Therapeutics, Wednesday August 31, 2022, 18.45-20.15, Hall Porto

Immunogenicity and Investigational AAV Gene Therapy

Chair: Benedikt Schoser, Munich, Germany

Welcome and Introductions
Benedikt Schoser, Munich, Germany

Immune Response: The Basics Benedikt Schoser, Munich, Germany

Potential Immunogenic Responses to Investigational AAV Gene Therapy Federico Mingozzi, Spark Therapeutics, Inc., United States

Approaches Under Investigation that May Mitigate Immunogenicity in Investigational AAV Gene Therapy

Antonio Toscano, Messina, Italy

Live Panel Q&A

All faculty

sponsored by

